My Career Paths - Lessons learned
26 November 2026 - Ghent
During this session, experienced professionals share their career journeys and their most valuable career lessons with the participants
Ina Vandenbroucke | Vice President Research & Development | Fujirebio Europe
Ina Vandenbroucke, PhD, is Vice President Research & Development at Fujirebio Europe and a member of Fujirebio’s Global Executive Management Team. With more than 20 years of experience in life sciences and diagnostics, she has built a career spanning scientific research, product development, operations and executive leadership.
Starting as a scientist, she went on to lead R&D and Operations teams at Janssen Diagnostics, Biocartis, Multiplicom, Agilent Technologies and Fujirebio. Her experience covers molecular and immunoassay diagnostics across genetics, virology, oncology and neurology, from early research and assay development through product launch, manufacturing and lifecycle management.
Along the way, she has helped scale growing organizations and led teams through acquisitions, integrations and transformation. She is passionate about developing people and teams, translating scientific innovation into impact for patients, and sharing the career choices and lessons that have shaped her own journey.
About Fujirebio
For more than 75 years, Fujirebio has been driving innovation in the field of in vitro diagnostics (IVD), delivering the biomarker expertise and diagnostic technologies that support healthcare worldwide. As a global leader in diagnostic innovation, Fujirebio develops and provides high-quality biomarkers, assays, and diagnostic solutions that enable earlier detection, more accurate diagnoses, and improved patient care.
With research and development centres in Japan, Europe, and the United States, Fujirebio is at the forefront of advancing diagnostics in areas such as neurodegenerative diseases, infectious
diseases, oncology, and other critical medical conditions. The company is widely recognised for its pioneering work in biomarkers for Alzheimer's disease and related neurological disorders.
By combining scientific excellence, strong clinical evidence, and strategic partnerships with leading diagnostic companies, Fujirebio ensures that innovative diagnostic solutions are accessible on diagnostic platforms worldwide. Through continuous investment in research and development, Fujirebio remains committed to transforming diagnostics and improving outcomes for patients around the globe.
Ina Vandenbroucke | Vice President Research & Development | Fujirebio Europe
Ina Vandenbroucke, PhD, is Vice President Research & Development at Fujirebio Europe and a member of Fujirebio’s Global Executive Management Team. With more than 20 years of experience in life sciences and diagnostics, she has built a career spanning scientific research, product development, operations and executive leadership.
Starting as a scientist, she went on to lead R&D and Operations teams at Janssen Diagnostics, Biocartis, Multiplicom, Agilent Technologies and Fujirebio. Her experience covers molecular and immunoassay diagnostics across genetics, virology, oncology and neurology, from early research and assay development through product launch, manufacturing and lifecycle management.
Along the way, she has helped scale growing organizations and led teams through acquisitions, integrations and transformation. She is passionate about developing people and teams, translating scientific innovation into impact for patients, and sharing the career choices and lessons that have shaped her own journey.
About Fujirebio
For more than 75 years, Fujirebio has been driving innovation in the field of in vitro diagnostics (IVD), delivering the biomarker expertise and diagnostic technologies that support healthcare worldwide. As a global leader in diagnostic innovation, Fujirebio develops and provides high-quality biomarkers, assays, and diagnostic solutions that enable earlier detection, more accurate diagnoses, and improved patient care.
With research and development centres in Japan, Europe, and the United States, Fujirebio is at the forefront of advancing diagnostics in areas such as neurodegenerative diseases, infectious
diseases, oncology, and other critical medical conditions. The company is widely recognised for its pioneering work in biomarkers for Alzheimer's disease and related neurological disorders.
By combining scientific excellence, strong clinical evidence, and strategic partnerships with leading diagnostic companies, Fujirebio ensures that innovative diagnostic solutions are accessible on diagnostic platforms worldwide. Through continuous investment in research and development, Fujirebio remains committed to transforming diagnostics and improving outcomes for patients around the globe.
Vanessa Vankerckhoven | CEO & Co-Founder | Idevax
Vanessa Vankerckhoven is Founder and CEO of Idevax. She holds a PhD in Medical Sciences from the University of Antwerp, Belgium. She’s a passionate entrepreneur and also holds a position as Guest Professor at the Faculty of Medicine & Health Sciences at the University of Antwerp. She has a profound interest in vaccinology, medical microbiology, infectious diseases, oncology and medical devices.Prior to founding Idevax, she founded Novosanis in 2013 as a spin-off from the University of Antwerp, Belgium. Novosanis is medical device company active in urine sample collection and preservation. She successfully led the company through the acquisition by Orasure Technologies Inc in Jan 2019 and remained CEO until October 2022.She started her career as Research & Innovation Manager at the Vaccine and Infectious Disease Institute (VAXINFECTIO) at the University of Antwerp, Belgium.
About IDEVAX
IDEVAX is an ISO13845 certified Belgian medical device company specializing in innovative and reliable delivery solutions for prophylactic, diagnostic and therapeutic applications. At the heart of the company is VAX-ID®, an award-winning patented CE marked device that simplifies intradermal injection. VAX-ID® ensures accurate, standardized, and user-independent skin delivery of medicinal products with a high ease of use and minimal training.
Vanessa Vankerckhoven | CEO & Co-Founder | Idevax
Vanessa Vankerckhoven is Founder and CEO of Idevax. She holds a PhD in Medical Sciences from the University of Antwerp, Belgium. She’s a passionate entrepreneur and also holds a position as Guest Professor at the Faculty of Medicine & Health Sciences at the University of Antwerp. She has a profound interest in vaccinology, medical microbiology, infectious diseases, oncology and medical devices.Prior to founding Idevax, she founded Novosanis in 2013 as a spin-off from the University of Antwerp, Belgium. Novosanis is medical device company active in urine sample collection and preservation. She successfully led the company through the acquisition by Orasure Technologies Inc in Jan 2019 and remained CEO until October 2022.She started her career as Research & Innovation Manager at the Vaccine and Infectious Disease Institute (VAXINFECTIO) at the University of Antwerp, Belgium.
About IDEVAX
IDEVAX is an ISO13845 certified Belgian medical device company specializing in innovative and reliable delivery solutions for prophylactic, diagnostic and therapeutic applications. At the heart of the company is VAX-ID®, an award-winning patented CE marked device that simplifies intradermal injection. VAX-ID® ensures accurate, standardized, and user-independent skin delivery of medicinal products with a high ease of use and minimal training.
| For job seekers | For employers | Join BCF Career Event |
| | | |
| Powered by: Hyphen Projects Privacy Policy Terms & Conditions Chamber of Commerce: 32110979 |
© Copyright 2025 by Hyphen Projects